

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy: Industry Analysis & Outlook

(2019-2023)

February 2019



Executive Summary

CAR-T cell therapy is the most promising and remarkable treatment in the areas of oncology. It is a treatment that uses cells from a person's own immune system to fight against cancer. CAR-T Cell therapy works on gene transfer technology that enhances the immune response of cancer affected patient by destroying tumor cells. In 2017, two CAR-T Cell therapies were approved by the Food and Drug Administration (FDA), one for the treatment of children with acute lymphoblastic leukemia (ALL) and the other for adults with advanced lymphomas.

CAR-T Cell market is majorly driven by an increasing number of cancer cases and high demand for effective therapy in this area. The increasing number of products in the clinical pipeline under development would act as a growth catalyst for the global market. The ability of therapy to treat recurrent cancers with high efficiency is also contributing significantly to the market growth.


CD19 is the most targeted antigen for a limited range of blood cancers. Hematological cancers indicate a highly competitive therapy segment as compared to solid tumors, in which it is little difficult to identify the antigens and will offer a vast market potential. With the recent launch of CAR-T cell therapies like Kymriah and Yescarta, the market is estimated to witness robust growth in the upcoming years.

The market exhibit huge potential for companies engaged in developing, manufacturing of CAR T cell therapies for cancer treatment. Upcoming novel products and technologies and the presence of big players in the market will result in intense competition in future.

The report "Global CAR-T Cell Market: Industry Analysis & Outlook (2019-2023)" by Koncept Analytics provides extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering The United States, Europe, and Japan region along with the global market. The report profiles the key players of the market including Novartis International AG, Bluebird Bio, Celgene Corporation and Gilead Sciences.


Rising number of cancer cases and proven effectiveness of T cell therapy supported the growth of global CAR-T cell therapy market.

Global CAR-T Cell Market Forecast by Value (2018-2023)




- The global CAR T cell market is expected to reach US\$... billion in 2023, increasing from US\$... billion in 2018 and is likely to grow at a CAGR of ...% for the period spanning 2018-2023.
- The global CAR-T Cell hematological malignancy market is anticipated to reach US\$... billion in 2023, increasing from US\$.... billion in 2018, growing at a CAGR of% for the period spanning 2018-2023.
- The global Kymriah revenue is anticipated to reach US\$... billion in 2023, increasing from US\$... billion in 2018, registering CAGR of% for the period spanning 2018-2023.

Global CAR-T Cell Hematological Malignancy Market Forecast (2018-2023)




Global Kymriah Revenue Forecast (2018-2023)




Increasing collaborative R&D and high unmet needs will drive the CAR-T cell therapy market globally..

The U.S. UCART19 Revenue Forecast (2023-2027)




- The U.S. UCART19 revenue is likely to reach US\$... million in 2027, increasing from US\$... million in 2023, growing at a CAGR of ...% for the period spanning 2023-2027.
- European CYAD-01 revenue for AML is expected to reach US\$... million in 2028, increasing from US\$... million in 2023, growing at a CAGR of ...% for the period spanning 2023-2028.
- The number of mCRC patients treated with CYAD-01 in Japan are likely to reach ... in 2028, increasing from.... in 2024.

Europe CYAD-01 Revenue for AML Forecast (2023-2028)



Japan Patients treated with CYAD-01 for mCRC Forecast (2024-2028)



Disclaimer

This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report.

We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.

Koncept Analytics
CS-36, First Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T: +91-120-4130959
M: +91-9811715635
vikas@konceptanalytics.com

www.konceptanalytics.com